BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 - Candlesense
BBIO Clinical trials

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on additional open-label extension data from ATTRibute-CM and two ePosters with ATTRibute-CM data at Month 30 will be shared at the European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain from August 29 - September 1, 2025.

Related Questions

How will the new ATTRibute‑CM extension data presented at ESC affect BridgeBio's near‑term stock valuation and trading volume? What does the month‑30 open‑label data indicate about efficacy and safety relative to existing ATTR cardiomyopathy treatments, and could it shift market share expectations? What regulatory or commercial milestones are likely to follow the ESC presentation, and how might they impact the long‑term upside for BBIO?
Find similar articles on Candlesense globenewswire